September 18, 2013
The European Commission's Seventh Framework Program will award $801,360 throughout three years to scientific software company Qlucore to develop algorithms for use in personalizing hepatitis C treatment. The company will work on mathematical and statistical algorithms for integrating information from genetic, proteomic, and clinical research data to provide clinicians with a mobile application that could be used at the point of care. Pharmaceutical companies currently are developing new hepatitis C drugs that would lead to more genetic and clinical variables to evaluate for patients and create a need for tools that could assist clinicians in prescribing custom treatments for each patient.
09.16.2013; Ryan McBride
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Separate and Unequal Access Frames Discussion at CROI Panel on U.S. HIV Care Cascade|
|CROI 2018: Highlights and What's Next for Advocates|
|Reported PrEP 'Failure' Most Likely a Lack of Proper Testing and Adherence|
|Injection Drug Use Among People Living With HIV: A Missed Opportunity to Save Lives|
|Statin Use Might Reduce Risk of Cancer in HIV-Positive People|
|Insurers and Pharmas Must Help Fix HIV Drug Pricing System, Advocates Say|